本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的，不可用于人类或动物的临床诊断或者治疗，非药用，非食用。
Reslizumab
英文名：
Cas号：241473-69-8
Cas号：241473-69-8
检测信息查询
| 货号 | 规格 | 货期 | 库存 | 价格 | 会员价 | 订购 |
| 1308132498-1mg | 0 | ￥25000 | 请登录 |
| 别 名 | |
| Cas号 | 241473-69-8 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 产品参数 | Description
Reslizumab (Sch 55700) is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. Reslizumab is effective in neutralizing the function of IL-5. Reslizumab inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM. Reslizumab has high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in the the Biacore surface plasmon resonance and Kinetic Exclusion Assay, respectively[1][2]. IC50 & Target IC50: 91.1pM (IL-5-dependent cell proliferation)[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Liddament M, et al. Higher Binding Affinity and in vitro Potency of Reslizumab for Interleukin-5 Compared With Mepolizumab. Allergy Asthma Immunol Res. 2019 Mar;11(2):291-298. [2]. Pérez de Llano LA, et al. Mepolizumab and reslizumab, two different options for severe asthma patients with prior failure to omalizumab. Allergy. 2019 Sep 4. |
| 性状 | Reslizumab (Sch 55700) 是靶向人白介素 5 (IL-5) 的人源化单克隆抗体，用于治疗嗜酸性粒细胞性哮喘。Reslizumab 可有效阻断 IL-5 的功能。Reslizumab 抑制 IL-5 依赖性细胞增殖，IC50 值约为 91.1pM。Reslizumab 对人 IL-5 具有高结合亲和力，在 Biacore 表面等离振子共振和动力学排斥分析中，KD 值分别为 109 pM 和 4.3 pM |
| 贮存 |
- 雷莫芦单抗 947687-13-0
- Human IgG1 Control
- Abatacept 332348-12-6
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠单抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
- Dupilumab 1190264-60-8
- 重组人FGF-ACIDIC
沪公网安备 31012002003054号